Migraine Treatment Drugs Market Trends

  • Report ID: 2752
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT

Migraine Drugs Sector: Growth Drivers and Challenges

Growth Drivers

Increase in the Female Population

Migraines are more frequent in women as compared to men. This migraine in women’s is assigned to the rising and falling levels of estrogen during menstruation, menopause and pregnancy. Further, before puberty the prevalence of migraine in males and females remains same, however the first migraine in females occur when their periods begin and after puberty, it increases in females almost three times than males. Therefore, with the increase in the population of females, number of migraineurs is anticipated to increase, thus, driving the growth of the market.

Increase in Awareness regarding Migraine

The rising awareness related to migraine and the drugs available for its treatment is one of the major factors accelerating the growth of market. A number of organisations, such as, American Headache Society, are taking measures to spread awareness related to migraine therapeutics and to provide support to the patients regarding the disorders related to headache. Moreover, financial burdens and bad environmental conditions are increasing the demand to cure stress and to aware people about mental health. Hence, awareness about migraine is estimated to drive the growth of market over the forecast period.

Challenges

Different Side Effects from Migraine drugs

Migraine treatment includes acute therapy and preventive therapy. Since, patients want to get faster or complete relief, without any adverse affects or drugs. However, frequent use of some medications can lead to the happening of disabling condition in the patients. The side effects of the medications depend on the specific drug. Taking multiple drugs together can cause excess of serotonin in the human body leading to life threatening conditions. Hence, side effects of the migraine drugs are likely to hamper the market growth over the forecast period.


Base Year

2024

Forecast Year

2025-2037

CAGR

11.6%

Base Year Market Size (2024)

USD 6.22 billion

Forecast Year Market Size (2037)

USD 25.91 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of migraine drugs is assessed at USD 6.83 billion.

Migraine Drugs Market size was over USD 6.22 billion in 2024 and is projected to reach USD 25.91 billion by 2037, growing at around 11.6% CAGR during the forecast period i.e., between 2025-2037.

North America industry is expected to dominate majority revenue share by 2037, due to increasing adoption of novel therapies and high prevalence of migraine.

The major players in the market are Pfizer Inc., Eli Lilly and Company, Eisai Co. Ltd., Amneal Pharmaceuticals Inc., Abbott Laboratories, Novarties International AG, Amgen Inc., Teva Pharmaceuticals Industries, Endo International Plc., and others.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos